GYBYS(SH:600332) Di Yi Cai Jing·2025-10-10 09:31Core Viewpoint - The trademark dispute over the "Wang Lao Ji" brand has escalated into an international battle, with both Jia Duo Bao Group and Wang Lao Ji Health Industry Company claiming ownership of the overseas trademark rights, highlighting the strategic importance of brand recognition in expanding into overseas markets [1][3][4]. Trademark Ownership Claims - Jia Duo Bao Group asserts that it acquired the overseas trademark rights in the 1990s and has registered the "Wang Lao Ji" trademark in 60 countries and regions [1]. - Wang Lao Ji Health Industry Company claims that the trademark owner is Guangzhou Baiyunshan Pharmaceutical Group and has registered the "Wang Lao Ji" and "WALOVI" trademarks in over 100 countries [3]. Legal Actions and Market Impact - Both companies are engaged in legal battles, with Jia Duo Bao claiming victories in multiple lawsuits in Canada and the EU, while Wang Lao Ji has initiated actions in 21 countries against Jia Duo Bao's alleged malicious registrations [3][4]. - The ongoing trademark dispute is seen as a strategic move to gain dominance in the overseas market, which is crucial for both companies as domestic competition intensifies [4]. Financial Performance - Wang Lao Ji Health Industry Company reported a revenue of 6.5 billion yuan in the first half of 2025, an increase of 8.4% year-on-year, with a net profit of approximately 1.3 billion yuan, up 15.8% [4]. - The company's revenue figures from 2022 to 2024 were 9.35 billion, 10.01 billion, and 8.76 billion yuan, respectively, indicating fluctuations in performance [4]. - Over the past decade, Wang Lao Ji's overseas market size has grown 6.5 times, with an annual compound growth rate exceeding 25% [4].